Supplemental Data

Name: Supplemental Data
Creator: Andrew Blauvelt
Published: 2023-12-20T15:56:42.674Z
Keywords: Dermatology

Blauvelt, Andrew; Ladizinski, Barry; Prajapati, Vimal; Laquer, Vivian; Fischer, Alison; Eisman, Samantha; Hu, Xiaofei; Wu, Tianshuang; Calimlim, Brian; Kaplan, Blair; Liu, Yingyi; Teixeira, Henrique; Liu, John; Eyerich, Kilian

doi:10.17632/6h4gtrzgdc.3

Supplemental Data

Published: 20 December 2023| Version 3 | DOI: 10.17632/6h4gtrzgdc.3

Contributors:

Andrew Blauvelt, Barry Ladizinski, Vimal Prajapati, Vivian Laquer, Alison Fischer, Samantha Eisman, Xiaofei Hu, Tianshuang Wu, Brian Calimlim, Blair Kaplan, Yingyi Liu, Henrique Teixeira, John Liu, Kilian Eyerich

Description

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

Supplemental Data

Description

Files

Categories

Licence